By Sherri Oslick ---
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Bayer Healthcare AG et. al. v. Teva Pharmaceuticals U.S.A., Inc.
1:07-cv-00195; filed April 5, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 4,990,517 ("7-(1-pyrrolidinyl)-3-Quinolone- and -Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives," issued February 5, 1991) and 5,607,942 (same title, issued March 4, 1997) following a paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Bayer's Avelox® (moxifloxacin hydrochloride, an antibiotic used to treat infection). View the complaint here.
Sanofi-Aventis et. al. v. Barr Laboratories Inc.
2:07-cv-01605; filed April 5, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,514,531 ("Controlled-release Dosage Forms Comprising Zolpidem or a Salt Thereof," issued February 4, 2003) following Barr's filing of an ANDA to manufacture a generic version of Sanofi-Aventis' Ambien CR® (controlled release zolpidem tartrate, used to treat insomnia). View the complaint here.
Merial Ltd. et. al. v. Intervet, Inc.
1:07-cv-00630; filed April 4, 2007 in the District Court of the District of Columbia
Infringement of U.S. Patent No. 7,192,594 ("Postweaning Multisystemic Wasting Syndrome and Porcine Circovirus from Pigs," issued March 20, 2007) based on Intervet's manufacture and sale of its Porcine Circovirus Vaccine Type 2. View the complaint here.
Otsuka Pharmaceutical Co., Ltd. v. Sun Pharmaceutical Industries Ltd.
3:07-cv-01516; filed March 30, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,006,528 ("Carbostyril Derivatives," issued April 9, 1991) following a paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Otsuka's Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia). View the complaint here.
Janssen L.P. et. al. v. Barr Laboratories Inc. et. al.
3:07-cv-01515; filed March 30, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,160,559 ("Controlled Release Galantamine Composition," issued January 9, 2007) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Janssen's Razadyne ER® (formerly Reminyl®) (galantamine hydrobromide, used to treat mild to moderate dementia of the Alzheimer's type). View the complaint here.